M. Ganapathi

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Mahrukh K. Ganapathi, M. K. Ganapathi, M K Ganapathi, Mahrukh K Ganapathi, Mahrukh Ganapathi, Mahrukh Karkaria Ganapathi
Publication record
104 papers · 2,679 citations · H-index 29

PAPERS

PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer
20224 citationsauthor #4
Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines
20200 citationsauthor #8
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
20204 citationsauthor #11
Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
20204 citationsauthor #5
RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers
202013 citationsauthor #6
Signal Transduction Mechanisms Regulating Cytokine-Mediated Induction of Acute Phase Proteins
20200 citationsauthor #1
Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
201913 citationsauthor #9
Abstract 1774: Targeting aurora A kinase (AAK) in platinum-resistant high grade serous ovarian cancer (HGSOC)
20190 citationsauthor #5
Immunotherapy clinical trials suggest predictive immune-related biomarkers are tissue specific.
20190 citationsauthor #3
HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
201831 citationsauthor #16
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
201859 citationsauthor #9
Abstract 4050: Immune microenvironment characteristics of primary tumor predict long-term disease-free survival in high-grade serous ovarian cancer (HGSOC)
20180 citationsauthor #2
Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1
201810 citationsauthor #12
Neurotensin signaling pathway as a potential therapeutic target in high-grade serous ovarian cancer
20181 citationsauthor #6
Abstract 5708:HOXA4 and HOXB3gene expression signature as a biomarker of tumor recurrence in patients with high-grade serous ovarian cancer (HGSOC) following primary cytoreductive surgery and first-line adjuvant chemotherapy
20170 citationsauthor #16
Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
201731 citationsauthor #12
Key intermediates of the insulin-like growth factor 2 (IGF2) signaling pathway are differentially expressed in high-grade serous carcinoma originating in the fallopian tube as compared to ovary
20170 citationsauthor #5
Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells
20163 citationsauthor #6
Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer.
20168 citationsauthor #3
Abstract 4828: Enhanced cytotoxicity following sequential treatment with filanesib and melphalan in human myeloma cell lines
20160 citationsauthor #5
Abstract 1186: Inhibition of topoisomerase 2β sensitizes acute myeloid leukemia cells to ATRA induced apoptosis independent of the MAPK/ERK pathway
20160 citationsauthor #6
Evaluation of homeobox (HOX) gene expression as a prognostic biomarker of time to recurrence (TTR) in high grade serous ovarian cancer (HGSOC) patients treated with adjuvant carboplatin plus paclitaxel (A-C/P).
20160 citationsauthor #12
Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high‐grade serous ovarian cancer
201634 citationsauthor #1
RNAseq identifies a unique molecular profile for high-grade serous carcinoma originating from serous tubal intraepithelial carcinoma
20160 citationsauthor #7
Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?
20150 citationsauthor #2
Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC)
20157 citationsauthor #9
Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs.
201418 citationsauthor #2
Abstract 4239: Differentiation and apoptosis induced by all-trans retinoic acid is associated with downregulation of peroxiredoxin 1 in myeloid leukemia cells
20140 citationsauthor #5
Mechanisms regulating resistance to inhibitors of topoisomerase II
201384 citationsauthor #2
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
2012128 citationsauthor #8
Differing Von Hippel Lindau Genotype in Paired Primary and Metastatic Tumors in Patients with Clear Cell Renal Cell Carcinoma
201217 citationsauthor #9
Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma
20120 citationsauthor #6
Abstract 2526: Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity
20110 citationsauthor #1
Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80‐Da modification at this site
20116 citationsauthor #9
Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML): Relationships to immunophenotype and treatment outcomes.
20110 citationsauthor #11
DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.
201089 citationsauthor #6
Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib.
20104 citationsauthor #7
CCL 2 Expression in Primary Ovarian Carcinoma Is Correlated with Chemotherapy Response and Survival Outcomes
20103 citationsauthor #12
Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors
201038 citationsauthor #3
CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.
201041 citationsauthor #12
Abstract 5431: Histone deacetylase inhibitor (HDAC) panobinostat (LBH589) enhances the antiproliferative effect of a topoisomerase II (topo II) inhibitor in doxorubicin-resistant HL-60 cells, despite high MDR expression
20100 citationsauthor #5
Abstract 1626: Tyrosine phosphorylation of RIN1 modulates the anti-proliferative effects of sorafenib and sunitinib in renal cell carcinoma (RCC)
20100 citationsauthor #8
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
200935 citationsauthor #7
Target identification by phosphoproteomics: RIN1 modulation of sorafenib-induced cytotoxicity in renal cell carcinoma.
20090 citationsauthor #7
VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts).
200925 citationsauthor #5
Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib
20089 citationsauthor #9
Casein kinase I δ/ɛ phosphorylates topoisomerase IIα at serine-1106 and modulates DNA cleavage activity
200838 citationsauthor #10
The von Hippel Lindau (VHL) gene status is not always identical in paired primary (P) and metastatic (M) lesion in patients with clear cell renal cell carcinoma (CCRCC)
20080 citationsauthor #8
Phosphorylation of tyrosine 656 in topoisomerase IIβ is required for enzymatic activity and anti-tumor drug sensitivity
20070 citationsauthor #10
Sorafenib treatment of clear-cell renal cell carcinoma (CCRCC) and colorectal carcinoma (CRC) cells: Differential effects on gene expression and cell death pathways
20071 citationsauthor #4
Downregulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest
200631 citationsauthor #13
Dysfunction of Lipid Raft Microdomains and Defective Apoptotic Signal Transduction in PNH.
20063 citationsauthor #3
48 POSTER Distinct gene expression profiles and cell death pathways in clear-cell renal cell carcinoma (CCRCC) and colorectal carcinoma (CRC) cells:r elationship to hypoxia, von Hippel Lindau protein (pVHL) expression and anti-tumor activity of sorafenib
20060 citationsauthor #5
493 POSTER Down regulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest
20060 citationsauthor #1
Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
200616 citationsauthor #7
In vivo characterization of site-specific phosphorylation in human topoisomerase IIβ
20050 citationsauthor #7
Targeted si-RNA mediated down-regulation of topoisomerase II α or β isozymes defines selectivity to inhibitors of the enzyme
20050 citationsauthor #9
Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells
200511 citationsauthor #8
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.
2005247 citationsauthor #9
Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin
200538 citationsauthor #11
213 von Hippel-Lindau (VHL) and p53 dependent cytotoxic effects of the proteasome inhibitor bortezomib (PS) in human renal cancer cells
20041 citationsauthor #5
203 Modulation of DNA damage induced apoptosis by the proteasome inhibitor bortezomib (PS) in human colorectal and non-small cell lung cancer cells is p53-dependent and NK-kB-independent
20040 citationsauthor #10
c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.
200312 citationsauthor #8
Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase IIα Regulates Enzymatic Activity and Drug Sensitivity*
200361 citationsauthor #11
Renal cell carcinoma (RCC) and telomerase activity: relationship to stage.
200313 citationsauthor #7
Telomerase activity in Stage II colorectal carcinoma
200231 citationsauthor #11
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.
20029 citationsauthor #7
Dephosphorylation of Rabbit Skeletal Muscle Phosphorylase Kinase
20010 citationsauthor #1
Roles of NF-κB and 26 S Proteasome in Apoptotic Cell Death Induced by Topoisomerase I and II Poisons in Human Nonsmall Cell Lung Carcinoma*
200145 citationsauthor #5
Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependent enzymes.
20017 citationsauthor #6
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
200118 citationsauthor #5
Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
199911 citationsauthor #7
Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
199811 citationsauthor #7
Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells.
19986 citationsauthor #4
Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
199814 citationsauthor #7
Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells
19989 citationsauthor #7
Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
199620 citationsauthor #1
Targeting proteins to mitochondria: a current overview.
199252 citationsauthor #18
Okadaic acid, an inhibitor of protein phosphatases 1 and 2A, inhibits induction of acute-phase proteins by interleukin-6 alone or in combination with interleukin-1 in human hepatoma cell lines.
199213 citationsauthor #1
Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines.
1991250 citationsauthor #3
Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells.
1991185 citationsauthor #1
Regulation of serum amyloid A (SAA) synthesis in Hep 3B cells by cytokines and corticosteroids.
19910 citationsauthor #2
Transforming Growth Factor‐β1 Affects Acute Phase Protein Synthesis and Glycosylation a
19903 citationsauthor #2
Transforming growth factor beta 1 regulates production of acute-phase proteins.
199084 citationsauthor #2
Induction of C-reactive protein by cytokines in human hepatoma cell lines is potentiated by caffeine.
199013 citationsauthor #1
The Acute Phase Response Is Mediated by Heterogeneous Mechanisms a
198981 citationsauthor #2
Regulation of Biosynthesis and Secretion of Human C-reactive Protein and Serum Amyloid A
19893 citationsauthor #2
Differential Modulation by Caffeine and Phorbol Esters of the Induction of Acute Phase Proteins by Cytokines a
19890 citationsauthor #1
Effect ofcytokines on glycosylation ofacutephaseproteins inhumanhepatoma cell lines
19890 citationsauthor #2
Effect of cytokines on glycosylation of acute phase proteins in human hepatoma cell lines.
198939 citationsauthor #4
Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines.
1988139 citationsauthor #1
Cloning and cDNA sequence of the dihydrolipoamide dehydrogenase component human alpha-ketoacid dehydrogenase complexes.
198880 citationsauthor #7
Heterogeneous nature of the acute phase response. Differential regulation of human serum amyloid A, C-reactive protein, and other acute phase proteins by cytokines in Hep 3B cells.
198878 citationsauthor #1
Regulation of rabbit acute phase protein biosynthesis by monokines.
198874 citationsauthor #2
Cloning of rat brain succinyl-CoA:3-oxoacid CoA-transferase cDNA. Regulation of the mRNA in different rat tissues and during brain development.
19878 citationsauthor #1
Monokines regulate glycosylation of acute-phase proteins
198796 citationsauthor #2
Induction of succinyl-coenzyme A:3-oxoacid coenzyme A-transferase during differentiation of 3T3-L1 cells.
19861 citationsauthor #1
Dephosphorylation and inactivation of phosphorylase kinase: subunit specificity of rabbit skeletal muscle protein phosphatases.
198411 citationsauthor #1
Isolation and characterization of a high molecular weight protein phosphatase from rabbit skeletal muscle.
198419 citationsauthor #2
Studies Of The Dephosphorylation Of Phosphorylase Kinase
19820 citationsauthor #1

TIMELINE

1979 20 citations

1980 38 citations

1981 19 citations

1982 0 citations

1984 30 citations

1986 1 citations

1987 104 citations

1988 371 citations

1989 123 citations

1990 100 citations

1991 435 citations

1992 65 citations

1996 20 citations

1998 40 citations

1999 11 citations

2001 70 citations

2002 40 citations

2003 86 citations

2004 1 citations

2005 296 citations

2006 50 citations

2007 1 citations

2008 47 citations

2009 60 citations

2010 175 citations

2011 6 citations

2012 145 citations

2013 84 citations

2014 18 citations

2015 7 citations

2016 45 citations

2017 31 citations

2018 101 citations

2019 13 citations

2020 21 citations

2022 4 citations

Unknown 0 citations

M. Ganapathi

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT